Teva Q309 Sales Up

To read the full article, please choose one of the following options:

Teva, Israel's largest generic drugmaker, has release its Q309 financial results, announcing a 22% increase in net sales from Q308, to US$3.55bn. BMI believes that the results indicate that the firm is faring well in difficult economic conditions and has gained considerably since the Barr acquisition in 2008.